1. Home
  2. PRTC vs ANSC Comparison

PRTC vs ANSC Comparison

Compare PRTC & ANSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • ANSC
  • Stock Information
  • Founded
  • PRTC 2015
  • ANSC 2021
  • Country
  • PRTC United States
  • ANSC United States
  • Employees
  • PRTC N/A
  • ANSC N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • ANSC
  • Sector
  • PRTC Health Care
  • ANSC
  • Exchange
  • PRTC Nasdaq
  • ANSC Nasdaq
  • Market Cap
  • PRTC 439.8M
  • ANSC 463.6M
  • IPO Year
  • PRTC N/A
  • ANSC 2023
  • Fundamental
  • Price
  • PRTC $17.90
  • ANSC $10.82
  • Analyst Decision
  • PRTC Buy
  • ANSC
  • Analyst Count
  • PRTC 1
  • ANSC 0
  • Target Price
  • PRTC $45.00
  • ANSC N/A
  • AVG Volume (30 Days)
  • PRTC 2.0K
  • ANSC 53.3K
  • Earning Date
  • PRTC 04-30-2025
  • ANSC 01-01-0001
  • Dividend Yield
  • PRTC N/A
  • ANSC N/A
  • EPS Growth
  • PRTC N/A
  • ANSC N/A
  • EPS
  • PRTC 0.21
  • ANSC 0.19
  • Revenue
  • PRTC $4,828,000.00
  • ANSC N/A
  • Revenue This Year
  • PRTC $35.98
  • ANSC N/A
  • Revenue Next Year
  • PRTC $115.38
  • ANSC N/A
  • P/E Ratio
  • PRTC $7.81
  • ANSC $56.59
  • Revenue Growth
  • PRTC 44.98
  • ANSC N/A
  • 52 Week Low
  • PRTC $13.30
  • ANSC $10.23
  • 52 Week High
  • PRTC $28.39
  • ANSC $10.93
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 46.07
  • ANSC 74.34
  • Support Level
  • PRTC $19.00
  • ANSC $10.70
  • Resistance Level
  • PRTC $19.80
  • ANSC $10.83
  • Average True Range (ATR)
  • PRTC 0.33
  • ANSC 0.02
  • MACD
  • PRTC -0.12
  • ANSC 0.00
  • Stochastic Oscillator
  • PRTC 16.30
  • ANSC 52.17

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About ANSC Agriculture & Natural Solutions Acquisition Corporation

Agriculture & Natural Solutions Acquisition Corp is a blank check company.

Share on Social Networks: